Highlights

  • Clarity reached the recruitment target for the main cohort expansion group in its SECuRE study on 8 October 2026.
  • The study evaluates copper-67 SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer.
  • A separate combination-treatment group continues recruiting participants receiving enzalutamide.
  • Interim August 2026 observations reported prostate-specific antigen declines in evaluable participants.
  • The candidate remains investigational, with clinical and regulatory requirements still to be addressed.

Clarity Pharmaceuticals Limited (ASX:CU6) develops copper-based radiopharmaceuticals for cancer imaging and treatment through its SAR technology platform. Its 2026 clinical work includes SAR-bisPSMA, which uses copper-64 for imaging and copper-67 for targeted therapy. On 8 October 2026, the company reported that the main cohort expansion group of its SECuRE prostate cancer study had met its recruitment target, while a separate combination-treatment group remained open.

SECuRE Main Group Reaches Recruitment Target

The Phase I/IIa SECuRE study is evaluating the safety and efficacy of copper-67 SAR-bisPSMA in metastatic castration-resistant prostate cancer (mCRPC). Clarity Pharmaceuticals (ASX:CU6) confirmed that 16 participants had enrolled in the cohort expansion main group, where they are being assessed for up to six cycles of an 8 GBq dose.

Recruitment continues for participants receiving the same radiopharmaceutical alongside enzalutamide, an androgen receptor pathway inhibitor. The October announcement also described continued recruitment in the combination-treatment group as part of the ongoing cohort expansion.

What the 2026 Clinical Findings Show

In its August 2026 update, Clarity Pharmaceuticals (ASX:CU6) presented an assessment of 19 participants treated at the 8 GBq dose level. Among those evaluable, 74% recorded a reduction of at least 25% in prostate-specific antigen (PSA), while 63% recorded a reduction of at least 50%. These results are early clinical observations rather than confirmation of an approved treatment.

Among 16 radiographically evaluable participants, the company reported an 81% disease-control rate, comprising stable disease or complete response/undetectable disease under the reported assessment methods. It described most related adverse events as mild or moderate and transient. Clarity Pharmaceuticals (ASX:CU6) stated that additional observations would be reported as participant data matured.

How the Copper Theranostic Platform Works

The SAR-bisPSMA platform combines a prostate-specific membrane antigen targeting molecule with Clarity’s SAR chelator technology. Copper-64 is used to visualise relevant lesions, while copper-67 is being investigated for treatment. Clarity Pharmaceuticals (ASX:CU6) is also developing SAR-Bombesin and SARTATE within its radiopharmaceutical pipeline, although the October enrolment update concerned SECuRE.

The distinction between diagnostic imaging and therapeutic dosing matters. The same targeting framework can support patient selection and subsequent treatment evaluation, but clinical performance, Manufacturing consistency and regulatory review must each be demonstrated for the relevant product and indication.

Clinical Development and Operational Considerations

The company is planning further clinical development based on preliminary SECuRE observations. For Clarity Pharmaceuticals (ASX:CU6), factors influencing development include the Maturity of efficacy and safety evidence, recruitment in the combination group, radiopharmaceutical Supply and the requirements of a potential registrational study.

Copper-64 SAR-bisPSMA and copper-67 SAR-bisPSMA are unregistered products. Their safety and efficacy have not been assessed for Marketing authorisation by relevant health authorities, and completing recruitment does not establish approval or commercial availability.

Key Insights

Clarity Pharmaceuticals (ASX:CU6) has reached a defined 2026 recruitment milestone in its copper-67 SECuRE program. The company’s reported early clinical observations provide information about tolerability and treatment response within a limited study population, while additional data, larger trials and regulatory assessment remain central to determining the program’s clinical role.